Neoventa Medical
Frida Svenningsson is a seasoned HR professional with extensive experience in people management and organizational development. Currently serving as Chief People Officer at Neoventa Medical since May 2023, Frida has previously held roles including People and Culture Manager at Pulsen Omsorg and HR Business Partner at Emerson Automation Solutions. Additional experience encompasses positions as HR Recruiter at Jeppesen, HR Specialist at Altran Sverige, and HR Intern at Semcon, alongside earlier roles in the beauty industry. Frida attained a Högskoleexamen in Organisations- och personalutvecklare i samhället from the University of Borås between 2012 and 2015.
This person is not in any teams
This person is not in any offices
Neoventa Medical
Neoventa Medical AB is a Swedish medical device company founded in 1997 by Professor KG Rosén, Physiologist, Paediatrician & Neonatologist, trained at the University of Gothenburg, Sweden. Professor Rosén started Medical device developments, as a way to secure the use of his profound knowledge gained from experimental and clinical research inthe field of Fetal Monitoring.Neoventa provides innovative fetal monitoring solutions and services that improve obstetric care. Their solutions are designed to promote patient safety through enhanced decision support together with a structured workflow. Every day across the globe, health care professionals use their unique solutions to ensure a good start in life.Their core competence lies in using the STAN fetal monitor to perform evidence-based ST Analysis of the fetal ECG as an adjunct to CTG, “a second pair of eyes” during childbirth. They are also the provider of disposable fetal scalp electrodes for internal fetal monitoring under the brand Goldtrace. Another important area of business is a comprehensive education and training program, Neoventa Academy, which includes e-learning with certification.Numerous studies have shown that ST Analysis as an adjunct to CTG during labour reduces the number of babies born with risk of neurological damage, results in fewer operative deliveries, less need for fetal blood sampling and simultaneously being cost effective. The STAN fetal monitor has been used to deliver over one million children since its introduction in Europe. Over 15,000 patients have been enrolled in randomized trials and over 100,000 patients have been enrolled in observational studies.